Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Schrödinger Discontinues The Clinical Development Program For SGR-2921 Which Was Being Evaluated In A Phase 1 Dose-escalation Study For Relapsed/Refractory Acute Myeloid Leukemia Or High-risk Myelodysplastic Syndromes, Citing Two Patient Deaths

Author: Benzinga Newsdesk | August 14, 2025 07:06am

Posted In: SDGR